(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy.
VYVDURA is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at home, and is the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of chronic inflammatory demyelinating polyneuropathy or CIDP.
CIDP is a progressive, immune-mediated rare and debilitating neuromuscular disorder of the peripheral nervous system. Patients experience a range of disabling mobility and sensory issues, including trouble standing from a seated position, pain and fatigue, and frequent tripping or falling.
VYVDURA is now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP.
argenx's VYVGART and VYVDURA portfolio was approved in Japan for three indications first country globally with access across three indications.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
